We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
First PD-1 inhibitor breezes across finish line.
- Authors
Sheridan, Cormac
- Abstract
The article offers information on the approval for Opdivo (nivolumab), a fully human IgG4 antibody that inhibits programmed death 1 (PD-1), for treating unresectable melanoma, developed by Ono Pharmaceutical and partner Bristol-Myers Squibb (BMS) in Japan under the Prescription Drug User Fee Act, on July 4, 2014. It mentions that Kyoto University's Tasuku Honjo elucidated the structure and function of PD-1, an immune checkpoint expressed on T cells.
- Subjects
JAPAN; IMMUNOGLOBULINS; DRUG approval; MELANOMA treatment; ONO Pharmaceutical Co. Ltd.; BRISTOL-Myers Squibb Co.
- Publication
Nature Biotechnology, 2014, Vol 32, Issue 9, p847
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0914-847